Drug Profile


Alternative Names: Belotecan hydrochloride; Camtobell; CKD 602; EQ-917; S-CKD602

Latest Information Update: 05 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chong Kun Dang
  • Developer Chong Kun Dang; Chonnam National University Hospital; OnKor Pharmaceuticals
  • Class Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Cervical cancer; Ovarian cancer; Small cell lung cancer
  • No development reported Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 13 Aug 2015 Phase-IIb development for Ovarian cancer (Late-stage disease) is ongoing in South Korea (NCT01630018)
  • 13 Aug 2015 No recent reports on development identified - Phase-I for Solid tumours in South Korea (PO)
  • 13 Aug 2015 No recent reports on development identified - Phase-II for Non-small cell lung cancer (Late-stage disease, Second-line therapy or greater) in South Korea (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top